We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cancer Research UK and Abcam Launch Custom Antibody Partnership to Accelerate Research
Product News

Cancer Research UK and Abcam Launch Custom Antibody Partnership to Accelerate Research

Cancer Research UK and Abcam Launch Custom Antibody Partnership to Accelerate Research
Product News

Cancer Research UK and Abcam Launch Custom Antibody Partnership to Accelerate Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cancer Research UK and Abcam Launch Custom Antibody Partnership to Accelerate Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cancer Research UK and Abcam plc have announced a new partnership for the development and commercialization of novel custom antibodies to support the acceleration of cancer research.

Under the terms of the partnership, Abcam will develop custom protein-based reagents to targets identified by Cancer Research UK-funded researchers. The resulting antibodies will support research to further the understanding of cancer biology, help generate new diagnostic tools, and potentially be the basis for novel therapies.

Tony Hickson, CBO at Cancer Research UK, said: “We are excited to be partnering with Abcam to expand our access to biological reagents and to create the tools our scientists need to help accelerate our understanding of cancer. Abcam’s antibody development capabilities and “end-to-end” expertise will help provide our researchers with antibody reagents that can be applied from early-stage R&D right through to the clinic.”

Dr John Baker, SVP Product Portfolio Innovation at Abcam, commented: “We are proud to be working with Cancer Research UK to support their scientists and to provide them with access to specific and validated reagents to help them achieve their next breakthrough faster.”

Abcam will, upon request, supply unique antibodies developed within the terms of the agreement to Cancer Research UK-funded researchers for an agreed period of exclusivity in relation to that antibody. Subsequently, Abcam’s global supply capability and co-location in major technology hubs throughout the world will enable these innovative reagents to be made readily accessible to the wider research and diagnostic development community.

Advertisement